[{"orgOrder":0,"company":"SiteOne Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"SiteOne Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"SiteOne Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"SiteOne Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"SiteOne Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"ST-2427","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"SiteOne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SiteOne Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"SiteOne Therapeutics \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"SiteOne Therapeutics","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"STC-004","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"SiteOne Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"","sponsorNew":"SiteOne Therapeutics \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"SiteOne Therapeutics \/ National Institute on Drug Abuse"}]

Find Clinical Drug Pipeline Developments & Deals by SiteOne Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The funding will be used for the development of SiteOne's selective NaV1.8 inhibitor, STC-004, an investigational, non-opioid treatment for acute and chronic pain conditions.

                          Brand Name : STC-004

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          May 18, 2023

                          Lead Product(s) : STC-004

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : National Institute on Drug Abuse

                          Deal Size : $15.0 million

                          Deal Type : Funding

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Under the terms of the agreement, the companies will work together to advance potent and selective inhibitors of sodium ion channel 1.7 (NaV1.7) as non-opioid therapeutics for the treatment of pain.

                          Brand Name : ST-2427

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          January 19, 2022

                          Lead Product(s) : ST-2427

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Vertex Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Funding will support the development of an inhaled formulation of SiteOne’s drug candidate for chronic cough through IND-enabling studies and toward the clinic.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          May 11, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Preclinical

                          Sponsor : National Institutes of Health

                          Deal Size : $1.7 million

                          Deal Type : Funding

                          blank